FEATURED COMPANIES
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
- MORE
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The availability of reimbursement programs for patients with osteoporosis will drive the market growth during the forecast period. Osteoporosis is the most prevalent among the geriatric population. Therefore, major markets such as the US, Germany, Japan, the UK, France, Canada, Spain, and other developed European countries are providing reimbursement schemes. The analysts have predicted that the osteoporosis drugs market will register a CAGR of almost 5% by 2023.
Market Overview
Increasing prevalence of osteoporosis
Osteoporosis prevalence has increased worldwide due to which it is considered a serious public health concern. Osteoporosis is more common in older women than in older men. The improved standards of healthcare facilities and sophisticated treatment options have increased the life expectancy rates, augmenting the aging population
Side effects of osteoporosis drugs
Side effects of bisphosphonates such as alendronate, ibandronate, risedronate, and zoledronic acid may include muscle pain, joint pain, nausea, difficulty swallowing, heartburn, irritation of the esophagus, and gastric ulcers. Also, these drugs can cause osteonecrosis of the jaw. The risk of osteonecrosis of the jaw in an individual increase with treatment periods longer than 5 years.
For the detailed list of factors that will drive and challenge the growth of the osteoporosis drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Market Overview
Increasing prevalence of osteoporosis
Osteoporosis prevalence has increased worldwide due to which it is considered a serious public health concern. Osteoporosis is more common in older women than in older men. The improved standards of healthcare facilities and sophisticated treatment options have increased the life expectancy rates, augmenting the aging population
Side effects of osteoporosis drugs
Side effects of bisphosphonates such as alendronate, ibandronate, risedronate, and zoledronic acid may include muscle pain, joint pain, nausea, difficulty swallowing, heartburn, irritation of the esophagus, and gastric ulcers. Also, these drugs can cause osteonecrosis of the jaw. The risk of osteonecrosis of the jaw in an individual increase with treatment periods longer than 5 years.
For the detailed list of factors that will drive and challenge the growth of the osteoporosis drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global metabolic disorder therapeutics market
Exhibit 02: Segments of global metabolic disorder therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Antiresorptive drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antiresorptive drugs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Anabolic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Anabolic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Late-stage pipeline drugs for osteoporosis
Exhibit 38: Patent expiry of osteoporosis drugs
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Amgen Inc. - Vendor overview
Exhibit 46: Amgen Inc. - Business segments
Exhibit 47: Amgen Inc. - Organizational developments
Exhibit 48: Amgen Inc. - Geographic focus
Exhibit 49: Amgen Inc. - Key offerings
Exhibit 50: Eli Lilly and Company - Vendor overview
Exhibit 51: Eli Lilly and Company - Business segments
Exhibit 52: Eli Lilly and Company - Organizational developments
Exhibit 53: Eli Lilly and Company - Geographic focus
Exhibit 54: Eli Lilly and Company - Segment focus
Exhibit 55: Eli Lilly and Company - Key offerings
Exhibit 56: Novartis AG - Vendor overview
Exhibit 57: Novartis AG - Business segments
Exhibit 58: Novartis AG - Organizational developments
Exhibit 59: Novartis AG - Geographic focus
Exhibit 60: Novartis AG - Segment focus
Exhibit 61: Novartis AG - Key offerings
Exhibit 62: Pfizer Inc. - Vendor overview
Exhibit 63: Pfizer Inc. - Business segments
Exhibit 64: Pfizer Inc. - Organizational developments
Exhibit 65: Pfizer Inc. - Geographic focus
Exhibit 66: Pfizer Inc. - Segment focus
Exhibit 67: Pfizer Inc. - Key offerings
Exhibit 68: Radius Health, Inc. - Vendor overview
Exhibit 69: Radius Health, Inc. - Organizational developments
Exhibit 70: Radius Health, Inc. - Key offerings
Exhibit 71: Validation techniques employed for market sizing
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Antiresorptive drugs - Market size and forecast 2018-2023
- Anabolic drugs - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
- Research methodology
- List of abbreviations
Exhibit 01: Global metabolic disorder therapeutics market
Exhibit 02: Segments of global metabolic disorder therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Antiresorptive drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antiresorptive drugs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Anabolic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Anabolic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Late-stage pipeline drugs for osteoporosis
Exhibit 38: Patent expiry of osteoporosis drugs
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Amgen Inc. - Vendor overview
Exhibit 46: Amgen Inc. - Business segments
Exhibit 47: Amgen Inc. - Organizational developments
Exhibit 48: Amgen Inc. - Geographic focus
Exhibit 49: Amgen Inc. - Key offerings
Exhibit 50: Eli Lilly and Company - Vendor overview
Exhibit 51: Eli Lilly and Company - Business segments
Exhibit 52: Eli Lilly and Company - Organizational developments
Exhibit 53: Eli Lilly and Company - Geographic focus
Exhibit 54: Eli Lilly and Company - Segment focus
Exhibit 55: Eli Lilly and Company - Key offerings
Exhibit 56: Novartis AG - Vendor overview
Exhibit 57: Novartis AG - Business segments
Exhibit 58: Novartis AG - Organizational developments
Exhibit 59: Novartis AG - Geographic focus
Exhibit 60: Novartis AG - Segment focus
Exhibit 61: Novartis AG - Key offerings
Exhibit 62: Pfizer Inc. - Vendor overview
Exhibit 63: Pfizer Inc. - Business segments
Exhibit 64: Pfizer Inc. - Organizational developments
Exhibit 65: Pfizer Inc. - Geographic focus
Exhibit 66: Pfizer Inc. - Segment focus
Exhibit 67: Pfizer Inc. - Key offerings
Exhibit 68: Radius Health, Inc. - Vendor overview
Exhibit 69: Radius Health, Inc. - Organizational developments
Exhibit 70: Radius Health, Inc. - Key offerings
Exhibit 71: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
- MORE
Global Osteoporosis Drugs Market 2019-2023
The analyst recognizes the following companies as the key players in the global osteoporosis drugs market: Amgen Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Radius Health, Inc..
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in strategic alliances.”
According to the report, one of the major drivers for this market is the reimbursement programs and coverage of drug by health insurance.
Further, the report states that one of the major factors hindering the growth of this market is the poor diagnosis and drug treatment rates.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global osteoporosis drugs market: Amgen Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Radius Health, Inc..
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in strategic alliances.”
According to the report, one of the major drivers for this market is the reimbursement programs and coverage of drug by health insurance.
Further, the report states that one of the major factors hindering the growth of this market is the poor diagnosis and drug treatment rates.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
Note: Product cover images may vary from those shown
LOADING...
